Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Warner-Lambert describes NK2 antagonists for obesity

Oct. 18, 1996

Antiobesity proteins described by Lilly

Oct. 18, 1996

Anorexigenic dihydropyridine compounds from Bristol-Myers Squibb

Oct. 18, 1996

Lilly claims compounds for women's health

Oct. 18, 1996

Atosiban efficacy in treating preterm labor

Oct. 11, 1996

Yamanouchi awaits marketing approval for new contraceptive

Oct. 11, 1996

Improved formulation of Testoderm available in U.S.

Oct. 11, 1996

Muse approvable for treatment of impotence

Oct. 11, 1996

Aldose reductase inhibitor in phase III at Fujisawa

Oct. 11, 1996

Antidiabetic agents from Yamanouchi's clinical pipeline

Oct. 11, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
New 5-HT2C receptor agonists reported in Hansoh patent
BioWorld Science
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...
Parabilis takes top spot, pricing largest biopharma IPO at $670M
BioWorld
Less than two months after Kailera Therapeutics Inc. made headlines with biopharma’s largest IPO to date, Parabilis Medicines Inc. has come along and surpassed...